ASMC Transfection Kit (Aortic Smooth Muscle Cells)

$229.00$1,494.00

Kit Size VolumePriceAdd to Cart
0.5 ml (Catalog #1707)$229.00
1.5 ml (Catalog #1708)$498.00
8.0 ml (Catalog #7022)$1,494.00
SKU: ASMC

Description

NOTE: To place order using Credit Card, P-Card, or Purchase Order – please choose kit size above and click “Add to cart” button. You can place order online without creating an account.

Transfection Reagent for ASMC Cells (Aortic Smooth Muscle Cells)

  • Two component formulation enhances lipid mediated transfection efficiency
  • Optimized easy-to-use transfection protocol provided for transfection of siRNA, DNA, mRNA, and microRNA
  • Kit includes Transfection Enhancer reagent and recommended transfection protocol
  • High transfection efficacy in the presence of serum
  • Expand your RNAi application with a reagent optimized for delivery of both siRNA and plasmid
  • Reproducible transfection results
  • Works well for standard reverse transfection and high-throughput applications
  • Download in vitro ASMC transfection protocol: [PDF]
  • Download PowerPoint presentation for ASMC cells transfection kit: [PPT]
  • Developed and manufactured by Altogen Biosystems

Transfection Efficiency:

Reagent exhibits at least 70% transfection efficiency of siRNA delivery. Transfection efficiency was determined by real-time RT-PCR.

Transfection Protocol and MSDS:

Download Altogen Biosystems ASMC Transfection Protocol: [PDF]

Download MSDS: [PDF]

ASMC Cell Line:

Human Aortic Smooth Muscle Cells are derived from tunica intima and tunica media of plaque-free aorta tissue. The tunica intima is the inner layer of the artery comprised of a lining, a network of connective tissue, and a layer of elastic fibers; the tunica media, or middle coat, is comprised mostly of smooth muscle cells and elastic fibers arranged in spiral layers. Human arterial smooth muscle cells are able to synthesize collagen, elastin, myosin, and glycosaminoglycan. ASMC cells respond to various factors by proliferating or differentiating. These cells are used to study of human vascular disorders such as atherosclerosis, angiogenesis, stroke, vascular biology and also diabetes. Human aortic smooth muscle cells are insulin resistant at the receptor level but sensitive to IGF1 and IGF2. Curcumin prevents the migration of human aortic smooth muscle cells by inhibiting of MMP-9 expression.

Data:

ASMC cell transfection kit

Figure 1. GAPD mRNA levels were quantified using real-time RT-PCR in the ASMC cells transfected with siRNAs targeting GAPD or non-silencing siRNA. Forty-eight hours post-transfection, the cells were harvested and analyzed by real-time RT-PCR for GAPDH mRNA expression levels. Data were normalized against the 18S rRNA signal. Control samples were either mock-transfected or untreated. Values are normalized to untreated sample. Data are means ± SD (n=3).

ASMC-cells-transfection-protocol

Figure 2. Protein expression of GAPDH in ASMC cells. DNA plasmid expressing GAPDH or siRNA targeting GAPDH were transfected into ASMC cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.

Altogen Biosystems:

Altogen Biosystems transfection and electroporation products for life sciences and cancer research. Transfection reagents are developed for individual cancer cell line and transfection protocols are optimized for maximum delivery efficiency. Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of proteins, DNA, mRNA, shRNA, siRNA, and other negatively charged biomolecules in  vitro and in vivo. Read more about transfection technology at Altogen’s Transfection Resource.

Selected in vivo transfection product citations (ALTOGEN® IN VIVO Transfection Kits used in the following publications):

  • Nature. 2008 454(7203):523-7. Innate immunity induced by composition-dependent RIG-I …Saito et al [PDF]
  • Am J Pathology. 2010 177(4):1870-80. Role of ocular complement factor H in a murine model … Lyzogubov et al [PDF]
  • Nature Biotechnology. 2011 29(4):341-5. Delivery of siRNA to the mouse brain by … Alvarez-Erviti et al [PDF]
  • Cancer Research. 2011 71(15):5144-53. Inhibition of miR-193a expression by… Iliopoulos et al [PDF]
  • RNA. 2010 16(11):2108-19. RNase L releases a small RNA from HCV RNA that refolds … Malathi et al [PDF]
  • Diabetologia. 2012 55(7):2069-79. The p47phox- and NADPH oxidase organiser 1 … Youn et al [PDF]
  • British Journal of Cancer. 2012 107(3):516-26. TIGAR induces p53-mediated cell-cycle … Madan et al [PDF]
  • Hypertension. 2014 63(2):353-61. Tissue transglutaminase contributes to … Liu et al [PDF]
  • Circulation Research. 2010 15;107(8). Kruppel-like factor-4 transcriptionally regulates … Cowan et al [PDF]
  • Hypertension. 2012 59(1):158-66. Role of uncoupled endothelial nitric oxide synthase … Gao et al [PDF]
  • Jounal of Biological Chemistry. 2012 287(4):2907. Chaperoning of mutant p53 protein … Gogna et al [PDF]
  • PLoS Pathogens. 2012 8(8) Uridine composition of the poly-U/UC tract of HCV RNA … Schnell et al [PDF]
  • J Proteome Res. 2012(11) Retinal proteome analysis in a mouse model of oxygen-induced … Kim et al [PDF]
  • J Transl Med. 2010 15;8:133. Prevention of hyperglycemia-induced myocardial apoptosis … Zhang et al [PDF]
  • Mol Cell Biol. 2013 33(7). SCO2 induces p53-mediated apoptosis by Thr845 phosphorylation … Madan et al [PDF]
  • Hypertension. 2015 65(2):430-9. Neurokinin 3 receptor and phosphocholine transferase… Parchim et al [PDF]
  • Gastroenterology. 2011 141(2) Differential type I interferon-mediated autophagic trafficking … Desai et al [PDF]
  • PLoS Pathog. 2014 10(10) Exosomes from hepatitis C infected patients transmit HCV … Bukong et al [PDF]

Altogen Labs Research Services:

Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).

Volume Options:

  • 0.5 ml (Catalog #1707)
  • 1.5 ml (Catalog #1708)
  • 8.0 ml (Catalog #7022)

Additional information

Kit Size (Volume)

0.5 ml (Catalog #1707), 1.5 ml (Catalog #1708), 8.0 ml (Catalog #7022)